Spots Global Cancer Trial Database for 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

Official Title: Impact of 68GA-PSMA-11 PET/CT on Initial and Subsequent Treatment Strategies of Patients With Prostate Cancer

Study ID: NCT04050215

Conditions

Biochemically Recurrent Prostate Carcinoma

Metastatic Prostate Carcinoma

Prostate Adenocarcinoma

Prostate Carcinoma

PSA Level Greater Than Fifty

PSA Progression

Stage IV Prostate Cancer AJCC v8

Stage IVA Prostate Cancer AJCC v8

Stage IVB Prostate Cancer AJCC v8

Interventions

Computed Tomography

Gallium Ga 68-labeled PSMA-11

Positron Emission Tomography

Questionnaire Administration

Study Description

Brief Summary: This phase II trial studies the impact of 68GA-PSMA-11 positron emission tomography (PET)/computed tomography (CT) scan on treatment strategies for patients with prostate cancer. Diagnostic imaging procedures, such as 68GA-PSMA-11 PET/CT scan, may help doctors plan the best treatment for prostate cancer.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the impact of gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) PET/CT on initial and subsequent treatment strategies of patients with prostate cancer. OUTLINE: Patients receive 68Ga-PSMA-11 intravenously (IV) and undergo PET/CT scan over 3 hours. Patients may be reenrolled in the study, if 68Ga-PSMA-11 PET/CT is performed for subsequent management decision. After completion of study, patients are followed up within 3-12 months.